



PATENT

## In the UNITED STATES PATENT and TRADEMARK OFFICE

APPLICANT: Qiu, et al.	EXAMINER: not yet assigned
SERIAL NO.: 09/877,681	ART UNIT: not yet assigned
FILING DATE: June 8, 2001	DOCKET NO.: 6437.US.P4
TITLE: <b>CONTROLLED RELEASE FORMULATION OF DIVALPROEX SODIUM</b>	I certify that this correspondence (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail addressed to the Assistant Commissioner for Patents, Washington, D.C., 20231 on the date shown below.
	<i>Noelle Mitchell</i> 8-17-01 Noelle Mitchell Date

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

In accordance with their duty of disclosure under 37 C.F.R. §1.56, and as authorized and encouraged under 37 C.F.R. §§ 1.97-1.98 and the provisions of MPEP §§ 609 and 707.05(b), Applicants submit herewith certain patent documents, publications and/or other information ("references") which the Patent and Trademark Office may wish to consider in examining the above-identified patent application. The identification of any reference herein is not intended to be and should not be understood as being an admission that such reference necessarily constitutes "prior art" within the meaning of applicable law.

The cited references are listed on attached form PTO-1449.

- ☐ A copy of each cited reference is provided;
- ☒ Copies of cited references are not provided because each has previously been made of record in the parent application, or is otherwise known to be in the Examiner's possession.

The Examiner is requested to review and evaluate each cited reference to make an independent assessment of the materiality of each, if any, to the examination of the above-identified application. The Examiner is requested to ignore any underscoring or highlighting which may have been done because such markings may or may not have any relationship to the subject matter of the present invention. The copies being submitted with this Statement are the best copies available at this time. Applicants respectfully request that (1) the references cited herein be made of record; (2) that the Examiner acknowledge his consideration of each reference by initialing and returning the enclosed copy of the PTO-1449 form; and (3) that such references appear on the printed patent as having been considered on the record.

With regard to payment of a fee:

- ☐ ☒ No fee is due because:
- ☐ ☒ This Statement is mailed within three months of the filing date of this application, or before the mailing date of a first office action on the merits (see 37 C.F.R. §1.97(b)).
- ☐ Applicants certify that each reference cited in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement. (see 37 C.F.R. §1.97(e)).
- ☐ This Statement is filed after the mailing date of a first Office Action on the merits but before the mailing date of either a final action or a Notice of Allowance (see 37 C.F.R. §1.97(c)) so a fee of **\$240.00** is specified by 37 C.F.R. §1.17(p).

If any fees are owed, or any credit is due pertaining to this case, please charge that fee or apply that credit to Deposit Account No. 01-0025. A duplicate sheet of this page is enclosed

Ross Products Division of  
ABBOTT LABORATORIES  
Dept. 108140-DS/1  
625 Cleveland Avenue  
Columbus, OHIO 43215-1724

Telephone: (614) 624-5686  
Facsimile: (614) 624-3074

Docket: 6437.US.P4


Respectfully submitted,



---

by J. Michael Dixon  
Reg. No. 32,410

FORM PTO-1449 (Rev. 2032)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 6437.US.P4	Serial No. 09/877,681
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant Qiu, et al.	
(Use several sheets if necessary)		Filing Date June 8, 2001	Group



## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date (if appro.)
	4,988,731	1/29/91	Meade			
	5,212,326	5/18/93	Meade			
	4,369,172	1/18/83	Schor et al			
	4,913,906	4/3/90	Friedman et al			
	5,009,897	4/23/91	Brinker et al			
	5,019,398	5/28/91	Daste			
	5,055,306	10/8/91	Barry et al			
	5,169,642	12/8/92	Brinker et al			
	5,185,159	2/9/93	Aubert et al			
	5,589,191	12/31/96	Ukigaya et al			

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Name	Class	Subclass	Translation (Yes No)
	WO 94/27587	08.12.94	PCT			
	WO 00/37055	29.06.00	PCT			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Bialer et al., Int. J. Pharmaceutics, 20: 53-63 (1984)
		Bialer et al., Biopharmaceutics and Drug Disposition, 6: 401-411 (1985)
		Bialer et al., Israel J. Med. Sci., 20: 46-49 (1984)
		Collins et al., Extended Release Formulations of Anticonvulsant Medications Clinical Pharmacokinetics and Therapeutic Advantages, CNS Drugs 2000 Sept 14 (3): 203-212
EXAMINER		DATE CONSIDERED

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.